Focus on Biohealthcare Sector in ETF Market
This week, in the domestic ETF market, Samsung Active Asset Management's 'KoAct Biohealthcare Active' saw a remarkable increase of 17.95%, capturing investors' attention. This surge is attributed to the successful clinical trial announcements and technology export deals in the biohealthcare sector. Notably, ABL Bio's significant technology transfer agreement with Eli Lilly of the U.S. positively impacted its stock price. Similarly, TIMEFOLIO Asset Management and NH-Amundi Asset Management recorded high growth rates of 14.75% and 14.02%, indicating strong investor optimism in bio stocks.
This week also marked the listing of five new ETFs, including Samsung Active Asset Management's 'KoAct U.S. Biohealthcare Active', reflecting an expansion of investment in the global bio industry and a shift in focus to high-growth potential areas. TIMEFOLIO Asset Management has rebranded its 'TIMEFOLIO Global Anti-Aging Bioactive ETF' to 'TIMEFOLIO Global Bioactive ETF', broadening its investment scope. The global bio industry is anticipated to grow to approximately $3.9 trillion by 2030, with substantial expansions expected in areas such as obesity treatments, cancer therapies, and rare disease treatments.
Related ETF
Related News
[ETF of the Week] Samsung Active Asset Management's 'KoAct Bio Healthcare Active' rises over 17%, ranked #1 in growth rate, bio strength - Business Post[ETF of the Week] Samsung Active Asset Management's 'KoAct Bio Healthcare Active' rises over 17%, ranked #1 in growth rate, bio strength
Related ETF
TIMEFOLIO Asset Management Changes Existing Product Name to 'TIMEFOLIO Global Bioactive ETF'TIMEFOLIO Asset Management has announced on the 14th that it will change the name of its existing TIMEFOLIO Global Anti-Aging Bioactive Exchange Traded Fund (ETF) to 'TIMEFOLIO Global Bioactive ETF'. This name change aims to clearly convey that the ETF actively invests across the entire global bio industry beyond merely the aging and anti-aging fields, thereby enhancing communication with investors. The global bio industry is considered to have entered a phase of structural growth. According to market research agencies, the global biotechnology market size is expected to reach approximately $2.1 trillion (approximately 3,092 trillion KRW) this year.